AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced it will receive a research grant of $4 million from The Vijay and Marie Goradia Charitable Foundation. The grant will support extending Part 1 of the ongoing Phase 2 VacSYn trial of ACI-7104, AC Immune’s anti-alpha-synuclein (a-syn) active immunotherapy, in early Parkinson’s disease (PD).
– Grant supports extension of Part 1 of Phase 2 VacSYn trial of ACI-7104
– Planned extension of Part 1 will assess long-term safety and efficacy of ACI-7104 for an additional 2 years
– Final data from Part 1 of VacSYn trial expected in H2 2026